Rob Collin

Postdoc opportunity in molecular therapy for EYS-associated retinal disease at Radboud university medical center (Nijmegen, Netherlands). The research project focuses on pathogenic variants in the EYS gene, a recurrent cause of autosomal recessive retinitis pigmentosa and progressive vision loss. The postdoc will help develop, test, and optimize therapeutic strategies for EYS-associated retinal disease using zebrafish models and patient-derived iPSC retinal organoids. Research methods include antisense oligonucleotide (ASO) and CRISPR/Cas-based molecular interventions, cell culture, iPSC and retinal organoid work, cloning, RT-PCR, Western blot, immunocyto-/histochemistry, and generation/maintenance of mutant zebrafish models. The role is based in the research group of prof. dr. Rob Collin in the Department of Human Genetics, with collaborations inside Radboudumc and internationally. Eligibility highlights: a PhD in Molecular Life Sciences is required, ideally with experience in molecular therapies and/or retinal research. Strong experience with retinal research, ASO or CRISPR/Cas9, iPSC-derived retinal organoids, and/or zebrafish is a plus. Applicants should be able to work independently and in a team, communicate well, analyze data critically, and write manuscripts and reports. Funding and contract: fixed-term contract for 2 years, scale 10, salary €3,724 - €5,867 per month, 32 - 36 hours per week. The post includes standard employment benefits such as holiday allowance, end-of-year bonus, travel reimbursement, public transport reimbursement, and home-working allowance. Deadline: 2026-09-13. Interviews are planned for the second half of September 2026 and the first half of October 2026. How to apply: submit the application form on the vacancy page. Include your CV and motivation letter, and state your anticipated PhD defense or thesis manuscript submission date if relevant.

PhD candidate position at Radboud University Medical Center in the Netherlands on targeted oligonucleotide delivery in inherited retinal diseases . The project sits at the intersection of biology , medical science , biomedical engineering , chemistry , and computer science , with a strong translational focus on developing new treatments for blindness. The PhD will be embedded in two research groups led by Prof. Rob Collin (Department of Human Genetics) and Prof. Roland Brock (Department of Medical Biosciences). The work includes AI-based protein design and modeling, recombinant protein expression and purification, retinal cell culture and retinal organoid models, confocal fluorescence microscopy, tissue-on-a-chip systems, nanoparticle formulation, and chemical conjugation strategies for oligonucleotide delivery. The position is part of the Lifelong VISION consortium, a large Dutch national project funded by the Ministry of Education, Culture and Science (2024–2033) aimed at developing genetic therapies, pathway-targeting treatments, and cell therapies for blindness. The consortium includes multiple Dutch research institutions and offers a broad multidisciplinary environment. Applicants should have a background in Biomedical Sciences and/or Molecular Life Sciences . Experience with tissue culture, microscopy, and protein structure is considered a strength. The role also requires initiative, proactive communication, and ownership of the project. A Certificate of Conduct (VOG) is required. This is a 4-year fixed-term PhD employment with a listed salary of €3,217–€4,077 (scale 10A). The vacancy closes on 2026-09-13 . Interviews are expected in the second half of September 2026, with second interviews in the first half of October 2026.